Category:Antineoplastic agents
Jump to navigation
Jump to search
group of chemical compounds | |||||
Upload media | |||||
Instance of |
| ||||
---|---|---|---|---|---|
Subclass of |
| ||||
| |||||
Subcategories
This category has the following 57 subcategories, out of 57 total.
A
- Acadesine (4 F)
- Alitretinoin (7 F)
- Altretamine (7 F)
- Anagrelide (5 F)
- Azaribine (3 F)
B
- Belzutifan (3 F)
- Bryostatins (7 F)
C
- Cabazitaxel (1 F)
- Cisplatin (49 F)
D
- Dabrafenib (7 F)
- Decitabine (6 F)
- Defactinib (2 F)
- Demecolcine (6 F)
- Docetaxel (12 F)
E
- Enasidenib (2 F)
- Encorafenib (3 F)
- Enocitabine (3 F)
G
- Gestonorone caproate (4 F)
H
- Hsp90 inhibitors (4 F)
I
- Illuidins (7 F)
- Imatinib (33 F)
- Imetelstat (4 F)
K
L
- Linsitinib (1 F)
M
- Megestrol acetate (7 F)
- Melengestrol (4 F)
- Melengestrol acetate (2 F)
- Midostaurin (4 F)
- Miriplatin (3 F)
- Mitotane (7 F)
- Mubritinib (3 F)
N
- Nafoxidine (6 F)
- Nocodazole (9 F)
P
- Pelretin (4 F)
R
- Repotrectinib (2 F)
S
- Sonidegib (3 F)
- Sparsomycin (4 F)
T
- Tamibarotene (3 F)
- Tirapazamine (6 F)
- Tretinoin (17 F)
V
- Vemurafenib (5 F)
- Venetoclax (4 F)
- Vismodegib (6 F)
- Vorasidenib (2 F)
Media in category "Antineoplastic agents"
The following 197 files are in this category, out of 197 total.
-
(±)-Mitotane Enantiomers Structural Formulae.png 2,099 × 620; 16 KB
-
1yy9.png 633 × 259; 68 KB
-
-
-
-
-
-
-
-
-
-
A-Comprehensive-Panel-of-Three-Dimensional-Models-for-Studies-of-Prostate-Cancer-Growth-Invasion-pone.0010431.s013.ogv 1 min 6 s, 524 × 384; 8.71 MB
-
-
-
-
-
-
A-novel-microtubule-de-stabilizing-complementarity-determining-region-C36L1-peptide-displays-srep14310-s2.ogv 25 s, 1,920 × 1,080; 8.73 MB
-
A-novel-microtubule-de-stabilizing-complementarity-determining-region-C36L1-peptide-displays-srep14310-s3.ogv 6.3 s, 1,920 × 1,080; 342 KB
-
A-novel-microtubule-de-stabilizing-complementarity-determining-region-C36L1-peptide-displays-srep14310-s4.ogv 6.3 s, 1,920 × 1,080; 1.05 MB
-
A-novel-microtubule-de-stabilizing-complementarity-determining-region-C36L1-peptide-displays-srep14310-s5.ogv 3.2 s, 1,920 × 1,080; 1.53 MB
-
A-novel-microtubule-de-stabilizing-complementarity-determining-region-C36L1-peptide-displays-srep14310-s6.ogv 3.2 s, 1,920 × 1,080; 2.12 MB
-
-
A-phenanthrene-derived-PARP-inhibitor-is-an-extra-centrosomes-de-clustering-agent-exclusively-1471-2407-11-412-S2.ogv 2 min 10 s, 512 × 512; 1.38 MB
-
-
Aceglatone.svg 512 × 471; 25 KB
-
-
-
-
Anthramycin.svg 765 × 390; 17 KB
-
-
-
-
-
Artificial-human-Met-agonists-based-on-macrocycle-scaffolds-ncomms7373-s2.ogv 15 s, 960 × 540; 2.45 MB
-
Aumolertinib.svg 945 × 565; 25 KB
-
-
-
-
Avutometinib ball-and-stick 7MFD.png 2,909 × 1,500; 639 KB
-
Avutometinib.svg 205 × 56; 15 KB
-
Belvarafenib.svg 264 × 70; 19 KB
-
Benzylguanine.svg 512 × 726; 15 KB
-
BI 811283 ball-and-stick 5K3Y.png 1,979 × 1,200; 532 KB
-
BI 811283.svg 184 × 124; 11 KB
-
Biosynthesis of nonproteinogenic amino acid.png 432 × 693; 12 KB
-
Brigimadlin.svg 810 × 550; 39 KB
-
Bropirimine structure.png 730 × 596; 7 KB
-
Bropirimine synthesis.png 1,647 × 266; 10 KB
-
Cedazuridine.svg 615 × 285; 13 KB
-
-
-
-
-
-
-
-
-
-
-
-
-
Cucurbitacin-I-Inhibits-Cell-Motility-by-Indirectly-Interfering-with-Actin-Dynamics-pone.0014039.s006.ogv 21 s, 1,114 × 460; 13.17 MB
-
-
Daniquidone.svg 634 × 317; 3 KB
-
-
Darinaparsin.svg 855 × 390; 17 KB
-
Dicycloplatin02.png 1,642 × 929; 88 KB
-
Enloplatin.png 692 × 269; 71 KB
-
Enloplatin.svg 115 × 62; 6 KB
-
Enzyme data for 4-substituted analogs.jpg 938 × 504; 49 KB
-
Enzyme data for monosubstituted 5-aryl analogs.jpg 1,173 × 866; 98 KB
-
Epacadostat.svg 512 × 212; 11 KB
-
Erbuzole structure.png 1,347 × 720; 16 KB
-
Exisulind structure.svg 512 × 292; 5 KB
-
Exogenous-Ether-Lipids-Predominantly-Target-Mitochondria-pone.0031342.s006.ogv 28 s, 480 × 360; 8.69 MB
-
Glasdegib.svg 512 × 188; 5 KB
-
Golcadomide.svg 512 × 195; 9 KB
-
-
-
Hitachimycin.svg 512 × 295; 8 KB
-
Iberdomide.svg 512 × 180; 8 KB
-
Ibritumomab tiuxetan structure.svg 434 × 201; 61 KB
-
Identification-of-pyrazolopyridazinones-as-PDEδ-inhibitors-ncomms11360-s1.ogv 9.0 s, 671 × 512; 2.61 MB
-
Identification-of-pyrazolopyridazinones-as-PDEδ-inhibitors-ncomms11360-s2.ogv 9.0 s, 671 × 512; 2.91 MB
-
Identification-of-pyrazolopyridazinones-as-PDEδ-inhibitors-ncomms11360-s3.ogv 9.0 s, 671 × 512; 3.52 MB
-
Identification-of-pyrazolopyridazinones-as-PDEδ-inhibitors-ncomms11360-s4.ogv 9.0 s, 671 × 512; 3.27 MB
-
Identification-of-pyrazolopyridazinones-as-PDEδ-inhibitors-ncomms11360-s5.ogv 9.0 s, 671 × 512; 4.61 MB
-
Identification-of-pyrazolopyridazinones-as-PDEδ-inhibitors-ncomms11360-s6.ogv 9.0 s, 671 × 512; 2.34 MB
-
-
-
-
In-vitro-discovery-of-promising-anti-cancer-drug-combinations-using-iterative-maximisation-of-a-srep14118-s5.ogv 12 s, 1,920 × 1,080; 3.29 MB
-
In-vitro-discovery-of-promising-anti-cancer-drug-combinations-using-iterative-maximisation-of-a-srep14118-s6.ogv 12 s, 1,920 × 1,080; 6.59 MB
-
In-vitro-discovery-of-promising-anti-cancer-drug-combinations-using-iterative-maximisation-of-a-srep14118-s7.ogv 12 s, 1,920 × 1,080; 3.44 MB
-
In-vivo-Bioimaging-as-a-Novel-Strategy-to-Detect-Doxorubicin-Induced-Damage-to-Gonadal-Blood-Vessels-pone.0023492.s003.ogv 1 min 29 s, 480 × 336; 2.73 MB
-
In-vivo-Bioimaging-as-a-Novel-Strategy-to-Detect-Doxorubicin-Induced-Damage-to-Gonadal-Blood-Vessels-pone.0023492.s004.ogv 5 min 14 s, 480 × 336; 11.62 MB
-
Irofulven.png 4,299 × 650; 48 KB
-
-
-
-
-
-
Ivosidenib.svg 512 × 385; 8 KB
-
Leptomycin B.svg 2,558 × 986; 4 KB
-
Linifanib skeletal.svg 314 × 133; 30 KB
-
Lobaplatin.svg 268 × 101; 48 KB
-
-
-
-
-
-
-
-
-
-
-
-
-
Longitudinal-tracking-of-single-live-cancer-cells-to-understand-cell-cycle-effects-of-the-nuclear-srep14391-s4.ogv 1 min 12 s, 120 × 120; 1.33 MB
-
-
-
-
-
-
Lurbinectedin structure.svg 512 × 357; 13 KB
-
Lurbinectedin.png 1,647 × 1,453; 141 KB
-
Mecanisme d'acció Pyr1.jpg 462 × 577; 52 KB
-
-
-
-
-
-
-
-
-
-
-
Mezigdomide.svg 512 × 200; 9 KB
-
Monomethylauristatin E.svg 512 × 249; 73 KB
-
Monomethylauristatin F.svg 1,105 × 600; 33 KB
-
Nandrolone 17-bis(2-chloroethyl)carbamate.svg 1,670 × 990; 29 KB
-
Navitoclax.svg 2,625 × 1,500; 40 KB
-
Nedaplatin 3D BS.png 2,385 × 1,878; 477 KB
-
Oblongifolin-C-inhibits-metastasis-by-up-regulating-keratin-18-and-tubulins-srep10293-s2.ogv 14 s, 1,365 × 1,024; 52.06 MB
-
Oblongifolin-C-inhibits-metastasis-by-up-regulating-keratin-18-and-tubulins-srep10293-s3.ogv 14 s, 1,365 × 1,024; 51.8 MB
-
Olutasidenib.svg 790 × 385; 19 KB
-
-
P-Tosylaminocaprylchlormethylketon Synthese.svg 410 × 199; 52 KB
-
Padeliporfin.png 1,767 × 1,944; 161 KB
-
Pegdinetanib non-peptide structure.svg 541 × 183; 39 KB
-
Picoplatin.png 1,126 × 872; 15 KB
-
-
-
-
-
Plicamycin.svg 2,576 × 1,705; 27 KB
-
Porfimer Sodium.png 4,195 × 1,593; 85 KB
-
Quisinostat.svg 512 × 242; 6 KB
-
RMC-9805.svg 413 × 244; 27 KB
-
Salinosporamide A Biosynthesis.png 1,568 × 1,330; 34 KB
-
-
-
-
-
Selinexor.svg 512 × 281; 7 KB
-
-
-
-
Streptovitacin A.svg 1,170 × 940; 19 KB
-
Structure-and-Function-of-ABCG2-Rich-Extracellular-Vesicles-Mediating-Multidrug-Resistance-pone.0016007.s005.ogv 2.4 s, 1,024 × 1,024; 277 KB
-
-
STX-140.svg 167 × 118; 22 KB
-
Tabla antineoplasicos.png 973 × 327; 18 KB
-
Talampanel skeletal.svg 512 × 507; 5 KB
-
Talirine skeletal.svg 1,207 × 561; 18 KB
-
Targaprimir 96.svg 1,568 × 832; 44 KB
-
Targaprimir-96-CA-Biotin (1).svg 1,568 × 1,249; 57 KB
-
Targaprimir-96-CA-Biotin (2).svg 1,574 × 1,049; 56 KB
-
Targaprimir-96-CA-Biotin (3).svg 1,574 × 1,049; 59 KB
-
-
-
Targeting-the-Nuclear-Export-Protein-XPO1CRM1-Reverses-Epithelial-to-Mesenchymal-Transition-srep16077-s4.ogv 19 s, 1,280 × 960; 1.31 MB
-
Targeting-the-Nuclear-Export-Protein-XPO1CRM1-Reverses-Epithelial-to-Mesenchymal-Transition-srep16077-s5.ogv 19 s, 1,280 × 960; 1.36 MB
-
Tesirine skeletal.svg 1,216 × 660; 21 KB
-
-
Trabectedin (2).svg 293 × 198; 47 KB
-
Trabectedin Biosynthesis.png 11,033 × 7,093; 2.96 MB
-
Trabectedin labeled-rings.gif 1,053 × 758; 14 KB
-
Trabectedin structure.svg 512 × 385; 13 KB
-
Trabectedin.svg 491 × 395; 34 KB
-
U-11,555 image.png 1,211 × 843; 16 KB
-
Uvaricin.svg 2,261 × 1,569; 3 KB
-
Vadimezan.png 561 × 438; 7 KB
-
Vapreotide.svg 512 × 461; 72 KB
-
Vintafolide.svg 512 × 497; 131 KB
-
Y-90 tacatuzumab tetraxetan structure.svg 292 × 174; 64 KB